Answers are grounded in this paper and cite their sources.
This review finds that miRNAs could support repair in multiple sclerosis, suggesting the need for human models to improve therapeutic strategies.
Beyond the potential role of microRNAs (miRNAs) as biomarkers, their participation in different biological and pathological processes observed in multiple sclerosis (MS) such as neuroinflammation, neurodegeneration and remyelination, makes them suitable candidates for therapeutic applications in neurorepair. Most studies addressing this reparative approach have been carried out using in vitro or in vivo model systems. However, functional differences between murine and human cells within the central nervous system (CNS) have been described, and certain mechanisms are distinctive in humans. The development of human models to investigate therapeutic interventions in neurological conditions including MS should be a priority to avoid failures. In this review, we provide a comprehensive summary of the advances in reparative therapeutic strategies for MS, including miRNAs and human models. We also discuss their benefits, the likely challenges they face and comment on possible mitigation strategies.
No takes yet. Share an insight, caveat, or question.
Martín et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: